Skip to content Skip to navigation

Analysis: U.S. move to loosen vaccine patents will draw drug companies to bargain - lawyers

May 7 2021

"I think the end result that most players are looking for here is not IP waiver in particular, it's expanded global access to the vaccines," says law professor and SIEPR senior fellow Lisa Larrimore Ouellette.